Modelling HCV elimination

Is it achievable and what role would a vaccine play?

Nick Scott

1

What is elimination?

- The World Health Organization have set some global HCV 'elimination' targets:
 - 80% reduction in HCV incidence by 2030 (30% by 2020)
 - 65% reduction in HCV-related deaths by 2030 (10% by 2020)



Where did these targets come from?


- Informed from modelling by the World Health Organization
- The WHO suggest that the elimination targets could be achieved (*globally*) if five synergistic service coverage targets are reached:

Service coverage targets	Current	2020	2030
Blood safety	^{89% o} sc Austral	ia has donations eened	100% of donations screened
Safe injections: percentage of injections administered with safety engineered devices in and out of health facilities		ready _{50%}	90% 💙
Harm reduction: number of sterile needles and syringes provided per PWID per year	20	200	300
HCV diagnosis	<5% diagnosed	30%	90%
HCV treatment	<1% rec treatm	hallenging area	80% of people with HCV treated
ce: WHO draft global health sector strategies viral titis, 2016–2021		Burnet I Medical Research.	

Core components for Australia

- Treatment
 - Direct-acting antivirals
- Testing
 - Antibody testing, RNA testing
- Harm reduction
 - Needle and syringe distribution, opioid substitution therapy
- Vaccines


Modelling can determine the interplay between these, and how they can best work together



HCV incidence target in Australia

Annual incidence

Treatment numbers: 4,700 per year




- In Australia, treatment scale-up must be among PWID to reach the WHO's incidence target.
- Targeting treatments is necessary.



HCV mortality target in Australia

Annual HCV-related deaths

Treatment numbers: 5,700 per year




- Need to also target people with late stage liver disease.
- Treating PWID also achieves the WHO mortality target because of the cases that are prevented.
 - This can save on countries' treatment budgets.




HCV cascade of care

Treatment scale-up models suggest it will be difficult but possible <u>BUT</u>, treatment can not be scaled up unless patients are in care.


- Consider programs to improve the cascade of care, e.g. screening programs to improve diagnosis.
- Identify and remove bottlenecks from the cascade.
 - How do we get the most people on treatment?
 - Which modalities of which programs are required, e.g. nurse-led models of care.




Current cascade of care





Projecting treatment scale-up alone



Projecting treatment scale-up alone








Harm reduction and vaccines can play a key role

- In terms of HCV transmission, vaccines have a similar effect to harm reduction:
 - Minimize infection / reinfection
- Benefit from once off administration for longer term protection (compared to maintaining NSP / OST coverage)
- A vaccine could be administered following treatment to increase the impact
 - Patients already engaged in care



Impact of vaccinating after treatment




- Even "minimal" coverage, vaccinating PWID following treatment, could have impact.
- Particularly important for settings with:
 - High prevalence
 - High cost treatments



Comparing vaccines and treatment

Treatment and vaccination numbers to halve prevalence in 15 years



- Prevalence can be halved with a vaccine alone.
- Increasing vaccine coverage reduces treatment requirements:
 - Increases the feasibility of elimination.



International settings

Models can be used to ask how we can achieve the elimination targets:

- What are the priority populations? Are there benefits in treating by:
 - Age group (birth cohort screening)
 - Disease stage
 - Geography
 - Risk population, e.g. treatment as prevention
- What is the most cost-effective way to scale-up treatments:
 - Through prioritisation of sub-populations.
 - Across delivery methods to sub-populations.
- How much will it cost to reach our targets? If we don't have that much:
 - What is the best we can do with what we have?
 - Does this change our priorities?



Conclusions

- Modelling shows that elimination is possible *but will require a multi*pronged approach.
- Treatment, testing, harm reduction and vaccines programs play synergistic roles:
 - Treatment can provide significant initial impact
 - Testing is required to find undiagnosed cases and prevent transmission
 - Future novel tests such as rapid RNA likely to be required
 - Harm reduction and vaccines are required to prevent infection / reinfection
 - Together the strategy becomes feasible
- Even more critical for international settings with limited resources.



Acknowledgements

- Burnet Institute
- People:
 - Joseph Doyle
 - Heidi Drummer
 - Margaret Hellard
 - Natasha Martin
 - Emma McBryde

- Alexander Thompson
- Peter Vickerman
- Amanda Wade
- Jack Stone

